Floatz logo

Cipralex

Schizophreniform Disorder

University of California, San FranciscoPhase 4 / ApprovedDormant
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Schizophreniform Disorder cohort.

Asset / SponsorPhaseRating
Raloxifene
Iris Sommer
Phase 4A
Olanzapine
Alkermes, Inc.
Phase 4A
Risperdal
Northwell Health
Phase 4BBB
SIMVASTATIN
Iris Sommer
Phase 3BB
17-beta-estradiol
Tangent Data
Phase 3BB

View all 34 →

Same molecule, other indications

Cipralex is also rated in:

Anxiety DisordersDormant
A
Indicative ·
81 / 100
View asset →
bipolar I disorderDormant
BBB
Indicative ·
77 / 100
View asset →
dysthymic disorderDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →